Dec 24, 2024

  • Sustainability
  • Corporate

Chugai Received Second Rating in Pharmaceutical Sector in the “DJSI World,” a Global ESG Investment Index

  • Chugai has been recognized as a highly sustainable company and ranked second in the world as a pharmaceutical company
  • Selected for five consecutive years in the “DJSI World,” comprised of the top five sustainable pharmaceutical companies in the world
  • Selected as “DJSI Asia Pacific” for the 10th time for seven consecutive years

TOKYO, December 24, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the company has been selected for five consecutive years as a constituent of “Dow Jones Sustainability Indices (DJSI) World,” the global version of DJSI, which is the world’s leading ESG investment index. Furthermore, Chugai has been selected as a constituent of “DJSI Asia Pacific,” the Asia-Pacific version, for the 10th time for seven consecutive years.

DJSI is a leading ESG index developed by S&P Dow Jones Indices (USA) and is one of the main investment selection criteria for investors worldwide who are interested in corporate sustainability. Companies are selected annually as a constituent based on the sustainability assessment of corporate economic, environmental, and social aspects.

In the pharmaceutical sector of the “DJSI World,” the top five sustainable companies have been selected as constituents, including Chugai. Chugai received the world’s second rating as a sustainable company among global pharmaceutical companies. In total, 321 companies (including 37 Japanese companies) were selected for the DJSI World. Three companies, including Chugai, have been selected for “DJSI Asia Pacific.” Chugai surpassed last year’s scores in areas such as product stewardship, human capital management, and tax strategy, and received high marks overall, especially in the social aspect.

The Company’s basic management policy is “creating shared value for Chugai and society” and aims to “realize advanced and sustainable patient-centric healthcare.” Chugai will continue dialogue with the stakeholders and contribute to the developing a sustainable society through our business activities.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Hideki Sato
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top